Mental & Cognitive Health — A Practical Guide to Treatment Options for Men

KAP combines ketamine — at sub-anesthetic doses — with structured psychotherapy. Sessions are typically 2–3 hours: a 45-minute dosing period followed by integration discussion. Ketamine produces a dissociative state that lowers psychological defenses and increases brain plasticity, allowing therapy to address depression, trauma, and treatment-resistant conditions that medication alone struggles with. Typical protocol: 6 sessions over 6–8 weeks, with ongoing maintenance for some patients. Stronger evidence than oral ketamine alone (without therapy).

Coverage is stronger than for most other men's-health categories. Most insurance covers traditional psychiatric care (medication management, therapy) with in-network providers. TMS is covered for treatment-resistant depression by Medicare and most commercial plans after typically 2 failed medication trials. Spravato (esketamine) is FDA-approved for treatment-resistant depression and covered by most insurers with documentation. Ketamine therapy (compounded/off-label) is almost universally cash-pay — $400–$700/session, 6 sessions standard.

TMS (transcranial magnetic stimulation) delivers focused magnetic pulses to the dorsolateral prefrontal cortex while you sit awake. Standard course is 30–36 daily sessions over 6–8 weeks. FDA-approved for treatment-resistant depression, OCD, and migraine. Response rate ~50–60% for depression resistant to SSRIs. Side effects: scalp discomfort at the treatment site, occasional headache, rare risk of seizure (mostly screened out at intake). Strong choice for patients who can't tolerate medication side effects.

Spravato is the FDA-approved S-isomer of ketamine delivered as a nasal spray, administered in a clinic under REMS protocols (mandatory 2-hour monitoring per session, certified provider, twice-weekly initial dosing). Compounded racemic ketamine (IV, IM, sublingual, oral) is used off-label, less expensive, often combined with KAP therapy, no REMS requirement. Spravato has FDA backing and insurance coverage; compounded ketamine has flexibility, lower cost, and therapy integration but is off-label. Effectiveness for treatment-resistant depression is comparable per studies.

Depends on severity. For mild depression, structured therapy (CBT, interpersonal therapy) alone matches medication outcomes in most studies. For moderate-to-severe depression, medication + therapy combined outperforms either alone. SSRIs are first-line because of safety profile and efficacy; SNRIs, bupropion, or mirtazapine become second-line based on side-effect profile and target symptoms. A clinic that prescribes without discussing therapy or measuring response is providing incomplete care.